The Promise of Reading the Entire Genome
The history of canine genetic testing has followed a trajectory familiar in many areas of technology: from expensive and specialized to increasingly accessible and comprehensive. The earliest breed-specific genetic tests detected single mutations using targeted assays. SNP (single nucleotide polymorphism) array genotyping then expanded coverage to hundreds of thousands of positions across the genome simultaneously, enabling population-level kinship analysis and genomic COI calculation. Now, whole-genome sequencing (WGS) is becoming affordable enough that individual breeders and breed health programs can consider it as a practical tool rather than a research-only technology.
Whole-genome sequencing reads every base in the dog’s approximately 2.8-billion-base-pair genome, not merely the selected positions covered by arrays. This completeness distinguishes WGS from all previous approaches and offers genuinely new capabilities for herding breed health management — though it also comes with interpretive challenges that require careful consideration.
What WGS Can Detect That Other Tests Cannot
Novel and Breed-Specific Variants
Panel genetic tests detect only the specific mutations they were designed to identify. A dog tested on a standard herding breed panel will receive clear or carrier status for each condition included, but will receive no information about mutations not on the panel. If a novel pathogenic variant exists in a particular bloodline — one that has not yet been published or characterized — panel testing will miss it entirely.
WGS, by contrast, detects all variants present in the genome relative to the reference sequence. Variant interpretation remains the limiting factor: of the millions of variants identified in any individual genome, the vast majority are benign or of unknown significance. However, for conditions with known causal variants, WGS provides a definitive answer not limited by panel design, and for families or breeds where novel conditions are suspected, WGS data provides the raw material for identifying new disease-causing mutations.
Structural Variants and Copy Number Changes
Many important genomic variations are not single nucleotide changes but larger structural alterations: duplications, deletions, inversions, or insertions of DNA segments. Some of these are missed or poorly detected by SNP arrays, while others cannot be reliably identified without the sequence context that WGS provides.
The CEA deletion, for instance, is a large structural deletion that could in principle be detected from WGS data. More broadly, structural variants affecting gene expression, dosage, or function are an underexplored source of breed-specific health variation that WGS will increasingly illuminate.
Comprehensive Runs of Homozygosity
Runs of homozygosity (ROH) — long stretches of the genome where both chromosomal copies are identical — are the genomic signature of inbreeding. WGS enables detection of ROH at higher resolution than SNP arrays, identifying shorter and more recent shared ancestors as well as the long ROH that reflect more remote common ancestry.
The distribution of ROH across the genome provides information not just about overall inbreeding level but about which ancestral individuals contributed most to the current animal’s genome. This connects directly to inbreeding coefficient calculations and population-level kinship management, where WGS data provides the highest-resolution picture available.
Pharmacogenomic Variants Beyond MDR1
The MDR1 mutation is the best-characterized pharmacogenomic variant in herding breeds, but the broader pharmacogenome — all the genetic variants affecting drug metabolism and response — is much larger. Variants in cytochrome P450 enzymes (which metabolize most drugs), drug transporters, and drug receptors collectively influence how a dog responds to dozens of medications.
WGS in principle identifies all variants in pharmacogenomically relevant genes, not just the MDR1 variant tested on standard panels. As pharmacogenomic knowledge in dogs expands — supported by research efforts parallel to the extensive human pharmacogenomics literature — WGS will increasingly enable genuinely personalized drug prescribing for individual dogs.
Canine WGS in Practice: Current State
The cost of WGS has fallen dramatically over the past decade, following the pattern first established in human genomics. Short-read sequencing (Illumina-platform) at 30x coverage, the standard for clinical-grade human WGS, is currently available for dogs at costs in the range of a few hundred to a few thousand dollars depending on the laboratory and coverage depth.
Several laboratories now offer canine WGS services targeted at breeders and veterinarians, though the landscape of providers, costs, and interpretive reports changes frequently. When evaluating WGS providers, relevant questions include:
Coverage depth: Higher-depth sequencing (more reads per base position) improves variant detection accuracy, particularly in regions of repetitive sequence. Clinical-grade human WGS standards typically specify 30x mean coverage; canine WGS at 15-20x is common in research contexts and may be adequate for many applications, but is less reliable for detecting heterozygous variants in low-complexity regions.
Reference genome version: The canine reference genome has been progressively improved through the Dog10K project and subsequent efforts. WGS data analyzed against a more complete and accurate reference genome will yield better variant calls. Ask which reference version the laboratory uses.
Variant interpretation pipeline: Raw variant calls (VCF files) are only the starting point. The interpretation pipeline determines which variants are clinically annotated, which are filtered as likely benign, and how uncertain results are reported. Comprehensive reports with breed-specific variant databases are more informative than generic outputs.
Data ownership and privacy: This is a particular concern in competitive breeding contexts. Understanding how the laboratory stores, uses, and potentially shares sequence data from your dogs is important before submitting samples.
Integration with Existing Testing Programs
Whole-genome sequencing does not replace established DNA testing programs for specific conditions — it complements them. For conditions with well-characterized mutations (MDR1, SOD1, prcd-PRA, CEA), validated panel tests remain cost-effective and reliable. WGS adds value at the edges: detecting novel variants, providing comprehensive pharmacogenomic data, enabling high-resolution population-level analysis, and serving as an archive that can be reanalyzed as new variants are discovered.
A practical integration approach for forward-thinking herding breed programs might include:
Panel testing for all breeding stock using validated assays for breed-relevant conditions. Our guide to canine DNA testing covers current panel options.
WGS for selected individuals where additional information is warranted: dogs from lines with suspected novel health conditions, dogs being considered for gene banking, or individuals identified as having low mean kinship in population-level analyses whose genetics are particularly worth preserving in detail.
Contribution to population databases. Several WGS-based breed population projects aggregate data from volunteer contributors, using the collective dataset to identify breed-specific variants, track allele frequencies, and support future research. Contributing WGS data from breeding dogs supports the knowledge base that benefits the entire breed community.
What WGS Cannot Do
Setting appropriate expectations for WGS is as important as communicating its capabilities.
WGS cannot fully predict complex traits. The polygenic traits most important to herding breed breeders — working ability, temperament, hip conformation, longevity — are influenced by hundreds or thousands of variants of small individual effect, interacting with each other and with the environment. WGS identifies all the variants but cannot synthesize them into a reliable prediction of most complex traits in individual dogs. As epigenetics and gene expression research continues to advance, the gap between genomic sequence and phenotypic outcome remains large for complex traits.
WGS cannot diagnose conditions where the genetic basis is unknown. For many herding breed health conditions, the causative genetic variants have not yet been identified. Sequencing an affected dog’s genome does not automatically reveal the cause of its disease; it generates data that, with appropriate analysis and comparisons to other affected and unaffected dogs, may eventually identify causative variants.
WGS interpretive standards in dogs lag human medicine. The clinical interpretation databases, validation standards, and specialist expertise built up for human WGS over two decades of clinical implementation do not have a direct parallel in canine genomics. This means that canine WGS reports necessarily carry more uncertainty about the significance of individual variants than human clinical WGS.
These limitations are real but not permanent. The future trajectory of canine genomic medicine points clearly toward increasing interpretive power as reference databases grow, analytical methods improve, and the community of canine genomics researchers expands. The breeders and breed health communities who invest in WGS data generation today are building the datasets that will enable the next generation of genomic health tools for their breeds.
The relationship between current investment in genetic data and future health improvements is one of the clearest examples in all of herding breed management of how long-term thinking pays dividends — not in the next litter but in the population that the next generation of breeders will inherit.